Cannabinoid and endocannabinoid system: a promising therapeutic intervention for multiple sclerosis

Stuart SchlossmanComplementary & Alternative therapies and devices for Multiple Sclerosis (MS)

 Hina Khan 1, Fareeha Khalid Ghori 1, Uzma Ghani 1, Aneela Javed 1, Saadia Zahid 2

Affiliations 

Abstract

Multiple sclerosis (MS) is a chronic and complex neurodegenerative disease, distinguished by the presence of lesions in the central nervous system (CNS) due to exacerbated immunological responses that inflict oligodendrocytes and the myelin sheath of axons. In recent years, studies have focused on targeted therapeutics for MS that emphasize the role of G protein-coupled receptors (GPCRs), specifically cannabinoids receptors. Clinical studies have suggested the therapeutic potential of cannabinoids derived from Cannabis sativa in relieving pain, tremors and spasticity. Cannabinoids also appear to prevent exaggerated immune responses in CNS due to compromised blood-brain barrier. Both, endocannabinoid system (ECS) modulators and cannabinoid ligands actively promote oligodendrocyte survival by regulating signaling, migration and myelination of nerve cells. The cannabinoid receptors 1 (CB1) and 2 (CB2) of ECS are the main ones in focus for therapeutic intervention of MS. Various CB1/CB2 receptors agonists have been experimentally studied which showed anti-inflammatory properties and are considered to be effective as potential therapeutics for MS. In this review, we focused on the exacerbated immune attack on nerve cells and the role of the cannabinoids and its interaction with the ECS in CNS during MS pathology.

Keywords: Cannabinoid; Cannabis sativa; Endocannabinoid system; Multiple sclerosis; Neuro-inflammation.

© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

References

    1. Banks WA (2015) The blood-brain barrier in neuroimmunology: tales of separation and assimilation. Brain Behav Immun 44:1–8. https://doi.org/10.1016/j.bbi.2014.08.007 – DOI – PubMed
    1. Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, Thompson AJ (2014) Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology 83(11):1022–1024. https://doi.org/10.1212/WNL.0000000000000768 – DOI – PubMed – PMC
    1. Chiurchiù V, van der Stelt M, Centonze D, Maccarrone M (2018) The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: clues for other neuroinflammatory diseases. Prog Neurobiol 160:82–100. https://doi.org/10.1016/j.pneurobio.2017.10.007 – DOI – PubMed
    1. Tullman MJ (2013) Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manage Care 19(2 Suppl):S15-20
    1. Kamińska J, Koper OM, Piechal K, Kemona H (2017) Multiple sclerosis—etiology and diagnostic potential. Postepy Hig Med Dosw (Online) 71:551–563. https://doi.org/10.5604/01.3001.0010.3836 – DOI

Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews